Sunifiram

Sunifiram, known by its development code DM-235, is a synthetic nootropic of the piperazine-amide class, structurally related to piracetam and to its sibling compound unifiram (DM-232) ^[1][3]. It emerged from medicinal chemistry work at the University of Florence aimed at designing ampakine-like cognition enhancers, and it is characterized in the literature as a novel antiamnesic and procognitive agent of exceptionally high potency ^[3][4].

Its research profile is built on animal models of learning and memory. In its foundational description, sunifiram prevented amnesia induced by scopolamine and several other agents in passive avoidance and Morris water maze tasks, with efficacy comparable to well-known nootropics such as piracetam, aniracetam, and rolipram but at far lower doses ^[3]. Later work showed that it improves cognitive deficits and restores hippocampal long-term potentiation in olfactory bulbectomized mice, a model of memory impairment ^[2], and structure-activity studies have generated analogues while confirming procognitive potency exceeding that of piracetam ^[1].

Sunifiram is an investigational research chemical with no regulatory approval and no established human clinical use; it is neither a licensed medicine nor an approved supplement ^[3][4]. It is typically supplied as a research-grade powder. Because it is active at very low doses and engages glutamatergic plasticity pathways, it has attracted interest as a potent cognitive enhancer, but its profile in humans is not well characterized, and its appeal rests on the striking potency and the clear mechanistic link to the molecular machinery of memory demonstrated in preclinical studies ^[1][2][3].

Sunifiram is a potent research compound with a reputation for a strong, fast cognitive kick at very small amounts. It's genuinely early-stage: it hasn't been through formal toxicology or human trials, so there's no long-term safety picture yet, and that's the main thing to keep in mind. Because it works at the NMDA glycine site, it's sensible to be cautious stacking it with other glutamate compounds or NMDA modulators. Legal status varies by country. Treat it as promising but experimental, with moderation as the smart default given how little formal data exists so far.

Sunifiram, also designated DM-235, was developed by researchers at the University of Florence around the year 2000 as part of a program to design piracetam-related cognition enhancers of far greater potency. Early pharmacological characterization reported antiamnesic activity roughly a thousand times higher than that of the most active piracetam-like compounds, active at doses in the hundredths-to-tenths of a milligram per kilogram range in rodents. Subsequent electrophysiology in 2013 clarified its mechanism, showing that it enhances hippocampal long-term potentiation through the glycine-binding site of the NMDA receptor with downstream CaMKII and PKC-alpha signaling. It has remained an experimental research compound and has never undergone clinical development, so no human efficacy or safety data exist.

Sunifiram enjoys a strong reputation among nootropic researchers precisely because of its potency: the finding that it can protect against amnesia at doses roughly a thousandfold lower than classic racetams made it one of the most striking piracetam derivatives ever reported. Its mechanism is unusually well mapped for a research chemical, with the glycine-site NMDA action and AMPA-facilitating, LTP-enhancing signaling documented in careful rodent studies. The honest caveat is that all of this evidence comes from animals and cell systems; there are no human trials, and its long-term safety is simply unknown. That combination of clear mechanism and high potency keeps it a compound of enduring scientific curiosity.